Drug treatment of pneumococcal pneumonia in the elderly

Drugs and Aging

Volumn 21, Issue 13, 2004, Pages 851-864

  Neralla, Sridhar ^a   Meyer, Keith C ^a,b  

^a University of Wisconsin Health   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AUTOLYSIN; BETA LACTAM ANTIBIOTIC; CLINDAMYCIN; COTRIMOXAZOLE; HYALURONIDASE; INTERLEUKIN 6; IRON BINDING PROTEIN; KETOLIDE; LEUKOTRIENE B4; MACROLIDE; NITRIC OXIDE; PENICILLIN BINDING PROTEIN; PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE; PNEUMOLYSIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SIALIDASE; TETRACYCLINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ANTIBACTERIAL ACTIVITY; BACTERIAL PNEUMONIA; COMMUNITY ACQUIRED PNEUMONIA; DRUG CHOICE; DRUG EFFICACY; ELDERLY CARE; HUMAN; IMMUNE RESPONSE; LOBAR PNEUMONIA; MINIMUM INHIBITORY CONCENTRATION; MUCOCILIARY CLEARANCE; MULTIDRUG RESISTANCE; PENICILLIN RESISTANCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SPUTUM SMEAR; STREPTOCOCCUS PNEUMONIAE; THORAX RADIOGRAPHY;

AGED; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, MICROBIAL; GERIATRICS; HUMANS; PENICILLIN RESISTANCE; PNEUMONIA, PNEUMOCOCCAL; RISK FACTORS; STREPTOCOCCUS PNEUMONIAE;

EID: 8444234673     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200421130-00003     Document Type: Review

References (83)

1. Swartz MN. Attacking the pneumococcus: a hundred years' war. N Eng J Med 2002; 346 (10): 722
2. Niederman MS, McCombs JS, Unger AN, et al. The cost of treating community acquired pneumonia. Clin Ther 1998; 20: 820-37
3. Niederman MS, Ahmed QAA. Community acquired pneumonia in elderly patients. Clin Geriatr Med 2003; 19: 101-20
4. Ruiz M, Ewig S, Marcos MA, et al. Etiology of community acquired pneumonia: impact of age, co-morbidity, and severity. Am J Respir Crit Care Med 1999; 160: 397-405
5. Riquelme R, Torres A, El-Ebiary M, et al. Community acquired pneumonia in the elderly: a multivariate analysis of risk and prognostic factors. Am J Respir Crit Care Med 1996; 154: 1450-5
6. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Am J Respir Crit Care Med 2001; 163: 1730-54
7. Schwartz JS. Pneumococcal vaccine: clinical efficacy and effectiveness. Ann Intern Med 1982; 96: 208-20
8. Koivula I, Sten M, Leinonen M, et al. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med 1997; 103: 281-90
9. Gillespie SH, Balakrishnan I. Pathogenesis of pneumococcal infection. J Med Microbiol 2000; 40: 1057-67
10. Tuomanen E. Molecular and cellular biology of pneumococcal infection. Curr Opin Microbiol 1999; 2: 35-9
11. Kim JO, Weiser JN. Association of intrastrain phase variation in quantity of capsular polysaccharide and teichoic acid with the virulence of Streptococcus pneumoniae. J Infect Dis 1998; 177: 368-77
12. Weiser JN, Pan N, McGowan KL, et al. Phosphorylcholine on the lipopolysaccharide of Hemophilus influenza contributes to the persistence in the respiratory tract and sensitivity to serum killing mediated by C-reactive protein. J Exp Med 1998; 187: 631-40
13. Hakansson A, Kidd A, Wadell G, et al. Adenovirus infection enhances in vitro adherence of Streptococcus pneumoniae. Infect Immun 1994; 62: 2707-14
14. Engelich G, White M, Hartshorn KL. Neutrophil survival is markedly reduced by incubation with influenza virus and Streptococcus pneumoniae: role of respiratory burst. J Leukoc Biol 2001; 69: 50-6
15. Kostiukova NN, Volkova MA, Ivanova VV, et al. A study of pathogenic factors of Streoptococcus pneumoniae strains causing meningitis. FEMS Immunol Med Microbiol 1995; 10: 133-7
16. Jedrzejas M. Pneumococcal virulence factors: structure and function. Microbiol Molec Biol Rev 2001; 65: 187-207
17. Hammerschmidt S, Bethe G, Remane PH, et al. Identification of pneumococcal surface protein A as a lactoferrin binding protein of Streptococcus pneumoniae. Infect Immun 1999; 67: 1683-7
18. Briles DE, Hollingshead SK, King J, et al. Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis 2000; 182: 1694-701
19. Bhakdi S, Tranum-Jensen J. Membrane damage by pore forming bacterial cytolysins. Microb Pathog 1986; 1: 5-14
20. Alcantara RB, Preheim LC, Gentry MJ, et al. Role of pneumolysin's complement activating activity during pneumococcal bacteremia in cirrhotic rats. Infect Immun 1999; 67: 2862-6
21. Braun JS, Novak R, Gao G, et al. Pneumolysin, a protein toxin of Streptococcus pneumoniae, induces nitric oxide production from macrophages. Infect Immun 1999; 67: 3750-6
22. Tomasz A, Saukkonen K. The nature of cell wall derived inflammatory components of pneumococci. Pediatr Infect Dis J 1989; 8: 902-3
23. Tuomanen EI, Austrian R, Masure R. The pathogenesis of pneumococcal infection. N Engl J Med 1995; 332: 1280-4
24. Bergeron Y, Ouellet N, Deslauriers AM, et al. Cytokine kinetics and other host factors in response to pneumococcal pulmonary infection in mice. Infect Immun 1998; 66: 912-22
25. Meyer KC. The role of immunity in susceptibility to respiratory infection in the aging lung. Respir Physiol 2001; 128: 28-31
26. Meyer KC. Lung infections and aging. Aging Res Rev 2004; 3: 55-67
27. Feldman. C. Pneumonia in the elderly. Clin Chest Med 1999; 20: 563-73
28. Fein AM. Pneumonia in the elderly: special diagnostic and therapeutic considerations. Med Clin North Am 1994; 78: 1015-33
29. Esposito AL. Pulmonary host defenses in the elderly. In: Niederman MS, editor. Respiratory infections in the elderly. New York: Raven Press, 1991: 25-44
30. Riquelme R, Torres A, El-Ebiary M, et al. Community acquired pneumonia in the elderly: clinical and nutritional aspects. Am J Respir Crit Care Med 1997; 156: 1908-14
31. Kikuchi R, Watabe N, Konno T, et al. High incidence of silent aspiration in elderly patients with community acquired pneumonia. Am J Respir Crit Care Med 1994; 150: 251-3
32. Metlay JP, Schulz R, Li YH, et al. Influence of age on symptoms at presentation in patients with community acquired pneumonia. Arch Intern Med 1997; 157: 1453-9
33. Lim WS, Macfarlane JT. Defining prognostic factors in the elderly with community acquired pneumonia: a case controlled study of patients aged >75. Eur Respir J 2001; 17: 200-5
34. Starczewski AR, Allen SC, Vargas E, et al. Clinical prognostic indices of fatality in elderly patients admitted to the hospital with acute pneumonia. Age Aging 1988; 17: 181-6
35. Wataakunakorn C, Bailey TA. Adult bacteremic pneumococcal pneumonia in a community teaching hospital, 1992-1996. Arch Intern Med 1997; 157: 1965-71
36. Ruiz-Gonzalez A, Falguera M, Nogues A, et al. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia. Am J Med 1999; 16: 385-90
37. Hansman D, Bullen MM. A resistant pneumococcus [letter]. Lancet 1967; 11: 264-5
38. Song JH, Lee NY, Ichiyama S, et al. Spread of drug resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) study. Clin Infect Dis 1999; 28: 1206-11
39. Doern GV, Pfaller MA, Kugler K, et al. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis 1998; 27: 764-70
40. Thornsberry C, Sahm DF, Kelly LJ, et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenza, and Moraxella catarrhalis in the United States: results from the TRUST surveillance program, 1999-2000. Clin Infect Dis 2002; 34 (1 Suppl.): 4S-16S
41. Albanese BA, Roche JC, Pass M, et al. Geographic, demographic and seasonal differences in penicillin-resistant Streptococcus pneumoniae in Baltimore. Clin Infect Dis 2002; 34: 15-21
42. Nuorti JP, Butler JC, Crutcher JM, et al. An outbreak of multidrug resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents. N Engl J Med 1998; 338: 1861-8
43. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 6th ed. National Committee for Clinical Laboratory Standards (NCCLS). Approved Standard NCCLS document M7-A5. Wayne (PA): NCCLS, 2001
44. Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community acquired pneumonia in the era of pneumococcal resistance: a report from the drug-resistant Streptococcus pneumoniae therapeutic working group. Arch Intern Med 2000; 160: 1399-408
45. Ewig S, Ruiz M, Torres A, et al. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. Am J Respir Crit Care Med 1999; 159: 1835-42
46. Turett GS, Blum S, Fazal BA, et al. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with HIV seroprevalence. Clin Infect Dis 1999; 29: 321-7
47. Feikin DR, Schuchat A, Kolczak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000; 90: 223-9
48. Metlay JP, Hoffmann J, Cetron MS, et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2000; 30: 520-8
49. Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered and clinical outcome. Clin Infect Dis 2003; 37: 230-7
50. Appelbaum PC. Resistance among Streptococcus pneumoniae: implications for drug selection. Clin Infect Dis 2002; 34: 1613-20
51. Nagai K, Davies TA, Jacobs MR, et al. Effects of amino acid alterations in PBPs 1a, 2b, 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil and ceflacor in 18 clinical isolates of penicillin susceptible, intermediate and resistant pneumococci. Antimicrob Agents Chemother 2002; 46: 1273-80
52. Shortridge VD, Doern GV, Brueggemann AB, et al. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae from a multicenter antibiotic resistance surveillance study conducted in the United States 1994-1995. Clin Infect Dis 1999; 29: 1186-8
53. Nelson ML, Levy SB. Reversal of tetracycline resistance mediated by different bacterial tetracycline resistance determinants by an inhibitor of the Tet(B) antiport protein. Antimicrob Agents Chemother 1999; 43: 1719-24
54. Lonks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin resistant Streptococcus pneumoniae. Clin Infect Dis 2002; 35: 556-64
55. Janoir C, Zeller V, Kitzis MD, et al. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob Agents Chemother 1996; 40: 2760-4
56. Sahm DF, Peterson DE, Critchley IA, et al. Analysis of ciprofloxacin activity against Streptococcus pneumoniae after 10 years of use in the United States. Antimicrob Agents Chemother 2000; 44: 2521-4
57. Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 346: 747-50
58. Anderson KB, Tan JS, File TM, et al. Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community acquired pneumonia. Clin Infect Dis 2003; 37: 376-81
59. Ho PL, Tse WS, Tsang KW, et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-controlled study. Clin Infect Dis 2001; 32: 701-7
60. Hyde TB, Gay K, Stephan DS. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 2001; 286: 1857-62
61. Amsden GW. Pneumococcal macrolide resistance: myth or reality? J Antimicrob Chemother 1999; 44: 1-6
62. Schito AM, Schito GC, Debbia E, et al. Antibacterial resistance in Streptococcus pneumoniae and Haemophilus influenzae from Italy and Spain: data from the PROTEKT surveillance study, 1999-2000. J Chemother 2003 Jun; 15 (3): 226-34
63. Clark JP, Langston E. Ketolides: a new class of antibacterial agents for the treatment of community-acquired respiratory tract infections in a primary care setting. Mayo Clin Proc 2003; 78: 1113-24
64. Felmingham D. Microbiologic profile of telithromycin, the first ketolide antimicrobial. Clin Microbiol Infect 2001; 7 Suppl. 3: 2S-10S.
65. Verhaejen J, Verbist L. In vitro activity of the new ketolide telithromycin and other antibiotics against Streptococcus pneumoniae in Belgium. Acta Clin Belg 2001; 56: 349-53
66. Johnson AP, Warner M, Livermore DM. Activity of linezolid against multi-resistant Gram-positive bacteria from diverse hospitals in the United Kingdom. J Antimicrob Chemother 2000; 45: 225-30
67. Ho PL, Ng TK, Yung RWH, et al. Activity of linezolid against levofloxacin-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci in Hong Kong. J Antimicrob Chemother 2001 Oct 1; 48 (4): 590-2
68. Conte Jr JE, Golden JA, Kipps J, et al. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002; 46: 1475-80
69. Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003 Nov; 124: 1789-97
70. Bryan CS, Talwani R, Stinson S, et al. Penicillin dosing for pneumococcal pneumonia. Chest 1997; 112: 1657-64
71. Lacy MK, Lu W, Xu X, et al. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agent Chemother 1999; 43: 672-7
72. White RL, Enzweiler KA, Friedrich LV, et al. Comparative activity of gatifloxacin and other antibiotics against 4009 clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000. Diag Microbiol Infect Dis 2002; 43: 207-17
73. Martinez JA, Horcajada JP, Almela M, et al. Addition of a macrolide antibiotic to a beta-lactam based empiric antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36: 389-95
74. Stahl JE, Barza M, DesJardin J, et al. Effect of macrolides as part of initial empiric therapy on length of stay in hospitalized patients with community acquired pneumonia. Arch Intern Med 1999; 159: 2576-80
75. Artz AS, Ershler WB, Longo DL. Pneumococcal vaccination and revaccination of older adults. Clin Microbiol Rev 2003; 16: 308-18
76. Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of the pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003; 348: 1747-55
77. Mirzanejad Y, Roman S, Talot L, et al. Pneumococcal bacteremia in two tertiary care hospitals in Winnipeg, Canada. Chest 1996; 109: 173-8
78. Centers for Disease Control and Prevention. Influenza and pneumococcal vaccination levels among persons aged 65 and above: in the United States. MMWR Morb Mortal Wkly Rep 2002; 51 (45): 1019-24
79. Ortqvist A. Pneumococcal vaccination: current and future issues. Eur Respir J 2001; 18: 184-95
80. Powers DC, Anderson EL, Lottenbach K, et al. Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults. J Infect Dis 1996; 173: 1014-8
81. Shelly MA, Jacoby H, Riley GJ, et al. Comparison of pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults. Infect Immun 1997; 65: 242-7
82. Lottenbach KR, Mink CM, Barenkamp SJ, et al. Age-associated differences in immunoglobulin G1 (IgG1) and IgG2 subclass antibodies to pneumococcal polysaccharides following vaccination. Infect Immun 1999; 67: 4935-8
83. Briles DE, Tart RC, Swaitlo E, et al. PspA and PspC: their potential role for use as pneumococcal vaccines. Microb Drug Resist 1997; 3: 401-8